Germline genetic testing looks for DNA variants that were present from conception and can potentially be passed to children. These variants are usually found in nearly every cell, so testing commonly uses blood or saliva. Germline testing may confirm an inherited disorder, identify a future disease risk, show carrier status, or explain why a condition appears repeatedly in a family.
A positive result can affect more than the person tested. It may identify relatives who need surveillance, treatment, reproductive counseling, or targeted testing. However, inherited does not always mean inevitable. Some pathogenic variants have incomplete penetrance, and people with the same variant may develop different symptoms or remain unaffected. A negative result can be highly reassuring when a known family variant is excluded, but broader negative testing may leave residual risk. A variant of uncertain significance is not a confirmed inherited diagnosis. The result should be interpreted with personal history, family history, inheritance pattern, and the laboratory’s technical limits.
- Germline variants are present from conception and may be inherited from a parent or passed to children.
- Blood and saliva are common samples, but transplant history, blood cancer, or mosaicism may require another tissue.
- A pathogenic germline result may confirm disease, predict risk, or identify carrier status depending on the gene and inheritance pattern.
- A negative test for a known family variant is more informative than a negative broad panel when no family cause is known.
- Cascade testing uses a confirmed family variant to test biological relatives efficiently.
- A VUS should not be used as though it were a proven inherited risk.
Table of Contents
- What Germline Genetic Testing Means
- Germline Versus Somatic Testing
- Who May Benefit From Germline Testing
- How Germline Testing Is Performed
- Positive, Negative, and Uncertain Results
- Inheritance Patterns and Family Risk
- Cascade Testing and Family Communication
- Limitations, Privacy, and Next Steps
What Germline Genetic Testing Means
Germline DNA is the genetic material a person receives at conception. A germline variant may be inherited from an egg or sperm cell, or it may arise for the first time in the person, called a de novo variant. Because the variant is established early in development, it is usually present in cells throughout the body and can potentially enter the next generation.
Germline testing can answer different medical questions:
- Does an inherited variant explain current symptoms?
- Does a healthy person carry a familial risk variant?
- Is someone a carrier for an autosomal recessive or X-linked condition?
- Could a cancer diagnosis have an inherited cause?
- What is the chance that children or other relatives carry the same variant?
- Are reproductive testing options available for a known family condition?
The term “mutation” is still widely used, but clinical reports increasingly use “variant.” A variant becomes medically important only when evidence supports a harmful effect in a gene linked to the relevant condition.
Germline testing may focus on one known family variant, sequence a single gene, analyze a multigene panel, or use exome or genome sequencing. The broadest test is not always the best. The assay should match the condition, expected variant types, and reason for testing.
For example, a person with a strong family history of Lynch syndrome may need testing of mismatch-repair genes and EPCAM. A child with a distinctive single-gene syndrome may need focused sequencing plus deletion and duplication analysis. A person with multisystem disease and no clear diagnosis may benefit from exome or genome testing.
Germline findings can influence diagnosis, prevention, treatment, reproductive planning, and family care. They can also reveal uncertain or unexpected information. Pretest counseling should explain these possibilities before a sample is collected.
Germline Versus Somatic Testing
Germline and somatic testing examine different categories of genetic change. Germline variants are constitutional and potentially heritable. Somatic variants arise after conception in a subset of cells and are usually not passed to children.
Cancer provides the most common comparison. A tumor accumulates somatic mutations as it develops. Tumor sequencing may identify EGFR, KRAS, BRAF, HER2, or other changes that guide treatment. Most of these changes are confined to the tumor. A somatic genetic test therefore does not automatically establish inherited risk.
However, tumor testing can reveal a variant that may also be germline. A BRCA1, BRCA2, TP53, mismatch-repair, or other hereditary-cancer finding in a tumor may prompt separate testing of blood, saliva, or another non-tumor sample. The two tests answer different questions:
| Feature | Germline testing | Somatic testing |
|---|---|---|
| Origin of variant | Present from conception | Acquired in a cell lineage after conception |
| Common sample | Blood or saliva | Tumor tissue, bone marrow, or circulating tumor DNA |
| Can affect relatives | Yes, if inherited or transmissible | Usually no, unless the finding is also confirmed in germline DNA |
| Main uses | Diagnosis, inherited risk, carrier status, family testing | Tumor diagnosis, prognosis, treatment selection, monitoring |
The distinction can become complicated by mosaicism and clonal hematopoiesis. Mosaicism means a variant is present in some but not all cells. Clonal hematopoiesis involves acquired variants in blood-forming cells, often increasing with age. A blood result may therefore look germline when it is actually restricted to blood cells.
Bone-marrow or stem-cell transplantation creates another challenge because the person’s blood may contain donor DNA. A skin biopsy or another carefully selected tissue may be needed for reliable germline analysis. Accurate clinical information helps the laboratory choose the right sample and interpretation.
Who May Benefit From Germline Testing
Germline testing may be considered when a person’s symptoms, age, family pattern, pathology, or other findings suggest an inherited condition. Testing criteria vary by specialty and disorder.
Common indications include:
- A known pathogenic variant in a biological relative.
- Disease occurring at an unusually young age.
- Multiple relatives with the same or related condition.
- Bilateral, multifocal, or multiple primary cancers.
- Rare tumor types or pathology associated with hereditary syndromes.
- Sudden cardiac death, cardiomyopathy, arrhythmia, or very high cholesterol in a family.
- Congenital anomalies, developmental differences, intellectual disability, or unexplained neurologic disease.
- Recurrent metabolic crises, unusual biochemical findings, or a suspected inherited enzyme disorder.
- A reproductive partner known to carry a recessive condition.
- Tumor results that suggest a possible inherited variant.
Testing an affected person first is usually most informative. If the family has several relatives with breast cancer, for example, testing a relative who had early or bilateral disease is more likely to identify the familial cause than testing a healthy relative. Once the cause is found, targeted family testing becomes straightforward.
Healthy people may undergo predictive or presymptomatic testing when a family variant is known. This requires careful consent because the result may reveal future risk before symptoms appear. The distinction is important: predictive genetic testing may identify increased but incomplete risk, while presymptomatic testing may indicate a high likelihood of eventual disease for certain conditions.
Children are generally tested when the result can change care during childhood. Testing a healthy child for an adult-onset disorder without childhood intervention may be deferred so the future adult can decide. Family circumstances and professional guidance may affect this choice.
A family history that appears negative does not rule out inherited disease. Families may be small, relatives may be young, diagnoses may be unknown, the variant may come through a sex less likely to express the condition, or the variant may be de novo.
How Germline Testing Is Performed
The testing process begins with a defined clinical question and informed consent. A three-generation pedigree can reveal inheritance patterns, ages of onset, unaffected older relatives, ancestry, reproductive history, and which person is most informative to test.
Choosing the test
A known family variant calls for targeted testing. A highly specific phenotype may justify a single-gene test. A genetically heterogeneous condition may require a multigene panel. Exome or genome sequencing may be useful for complex, unexplained disease.
The method must cover expected variant types. Standard sequencing may not detect large deletions, duplications, repeat expansions, methylation abnormalities, balanced rearrangements, or low-level mosaicism unless those analyses are included.
Collecting the sample
Blood is commonly preferred because it provides high-quality DNA. Saliva or cheek cells may be convenient alternatives. The clinician should tell the laboratory about blood cancer, transfusion, transplant, or suspected mosaicism.
For prenatal or reproductive testing, samples may come from chorionic villi, amniotic fluid, embryos, or other specialized sources. These require strict sample identification and contamination controls.
Laboratory analysis
The laboratory extracts DNA, performs sequencing or another assay, checks quality, identifies variants, and classifies relevant findings. Interpretation incorporates the gene-disease relationship, variant evidence, zygosity, phase, inheritance, and phenotype.
Turnaround time ranges from one to several weeks for targeted or panel testing and may be longer for complex analyses. Urgent options may be available in neonatal intensive care or time-sensitive treatment settings.
Consent topics
Before testing, patients should understand:
- Possible positive, negative, uncertain, carrier, and secondary findings.
- Which genes and conditions are included.
- Whether adult-onset or unrelated findings can be declined.
- Family implications and possible cascade testing.
- Sample storage, data sharing, and reanalysis policies.
- Costs, insurance coverage, and follow-up care.
A germline result is durable information. The report may remain relevant for decades, even as its interpretation evolves.
Positive, Negative, and Uncertain Results
A germline report should describe the exact variant, classification, gene, condition, inheritance, and limitations.
Positive result
A pathogenic or likely pathogenic germline variant may:
- Confirm an inherited diagnosis.
- Establish increased future disease risk.
- Identify carrier status.
- Explain a person’s cancer predisposition.
- Guide treatment or surveillance.
- Create a targeted testing option for relatives.
The result must fit the inheritance pattern. One pathogenic variant may be sufficient for an autosomal dominant condition. Two variants are usually needed for an autosomal recessive disorder, and the laboratory may need to determine whether they are on opposite gene copies.
A positive result does not always predict severity. Penetrance, age of onset, sex, environment, and modifier genes can alter expression. Management should follow condition-specific guidance rather than a generic “mutation positive” label.
Negative result
A negative result means no reportable pathogenic finding was detected within the test’s scope. Its meaning depends on whether the familial variant is known.
A true negative occurs when a person tests negative for a specific pathogenic variant already identified in the family. The person usually did not inherit that familial risk, although ordinary population risk and unrelated family factors remain.
An uninformative negative occurs when no family cause is known. The result may leave substantial residual risk because the test could miss certain variant types, the causal gene may not have been included, or science may not yet recognize the cause.
Variant of uncertain significance
A VUS is not a confirmed diagnosis. It generally should not change medical management or be used for predictive testing in healthy relatives. Selected family testing may help classification if the laboratory identifies an informative strategy. More information appears in the VUS result guide.
Secondary findings
Broad sequencing can identify a pathogenic variant unrelated to the original reason for testing. These findings may reveal preventable cancer or cardiac risk. Consent should address whether they will be analyzed and returned, and a positive secondary result should receive its own confirmation and care plan.
Inheritance Patterns and Family Risk
Family risk depends on the gene, variant, penetrance, and inheritance pattern. The percentages describe transmission, not guaranteed illness.
Autosomal dominant
One pathogenic variant can cause or increase risk. Each child of a carrier generally has a 50% chance of inheriting the variant. Men and women can be affected. Reduced penetrance can make the condition appear to skip generations.
Autosomal recessive
Two pathogenic variants are generally required. When both parents are carriers for the same condition, each pregnancy has a 25% chance of being affected, a 50% chance of producing a carrier, and a 25% chance of inheriting neither familial variant.
X-linked
Risk depends on which parent carries the variant, the child’s chromosomes, and the gene’s biology. Some heterozygous females remain unaffected, while others develop symptoms because of X-inactivation or the specific disorder.
Mitochondrial
Mitochondrial DNA is usually inherited from the mother. A mother with an mtDNA variant may pass it to all children, but the proportion of altered mitochondrial DNA can vary and influence severity. Fathers generally do not transmit mtDNA.
De novo and mosaic variants
A de novo variant appears in the tested person but not in parental blood samples. It may still be passed to that person’s children. Recurrence risk for parents is often low but not zero because of germline mosaicism.
A mosaic variant may be present in only some tissues. Transmission risk depends on whether egg or sperm cells are involved. Testing blood alone may not reveal the full pattern.
Risk figures should be tailored to the condition. A 50% chance of inheriting a variant is not always a 50% chance of developing disease because penetrance may be incomplete.
Cascade Testing and Family Communication
Cascade testing is the stepwise testing of biological relatives after a pathogenic or likely pathogenic germline variant is identified. It is one of the most efficient uses of genetic information because relatives can receive targeted testing for the exact family variant.
The process often begins with first-degree relatives: parents, siblings, and children. If a relative tests positive, testing expands through that branch of the family. If the person tests negative for the family variant, their descendants usually do not need testing for that variant.
Benefits include earlier surveillance, preventive treatment, reproductive information, and reassurance for noncarriers. Despite these benefits, many eligible relatives never receive testing. Barriers include cost, distance, limited genetics services, family conflict, inaccurate contact information, fear, language differences, and uncertainty about who should initiate communication.
The tested person is commonly asked to inform relatives because clinicians may be restricted by confidentiality rules. A family letter can provide:
- The gene and exact variant.
- The associated condition.
- Which relatives may be at risk.
- The recommendation for genetic counseling and targeted testing.
- A copy of the laboratory report or instructions for obtaining it.
The message should avoid predicting that a relative has the condition. It should explain that testing is available because of a confirmed family finding.
The 2025 ESHG recommendations describe cascade counseling and testing as a process rather than a single laboratory order. The process includes preparing the first tested person, supporting family communication, arranging access, and interpreting each relative’s result.
Children may be included when the result affects childhood care. Adult relatives retain the right not to know. Families may need time and repeated opportunities rather than one urgent request.
Limitations, Privacy, and Next Steps
Germline testing cannot identify every inherited cause. Technical limits include incomplete coverage, hard-to-sequence regions, low-level mosaicism, repeat expansions, structural variants, pseudogenes, and methylation abnormalities. Interpretive limits include unknown genes, disputed gene-disease relationships, and ancestry gaps in reference databases.
A negative result should prompt a review of what was actually tested. Possible next steps include deletion and duplication analysis, repeat-expansion testing, chromosome studies, RNA analysis, biochemical testing, exome or genome sequencing, testing another tissue, or reanalysis after new evidence emerges.
Privacy deserves attention because germline data are identifying and shared across biological families. Patients should ask:
- Who can access the result?
- Will the sample or data be retained?
- Can the data be used for research?
- What legal protections apply to employment and insurance?
- Are life, disability, or long-term-care insurance covered by those protections?
- How are family findings communicated while preserving confidentiality?
Rules differ by country and can change. Testing decisions should be made with current local information.
After a positive result, the care plan may include condition-specific surveillance, treatment, specialist referral, family testing, and reproductive counseling. After a negative result, medical care may still follow clinical or family-history risk. After a VUS, management should remain based on established evidence while the finding is documented for possible reevaluation.
Keep the full laboratory report. The exact variant notation, transcript, classification, laboratory, and date are necessary for family testing and future review. Ask whether the laboratory issues amended reports and who is responsible for recontact.
Germline testing is most useful when it creates a clear chain from result to action. A diagnosis should connect to care. A family-risk result should connect to targeted testing. A negative result should connect to residual-risk assessment. An uncertain finding should connect to proportionate follow-up rather than unsupported intervention.
References
- Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline 2024 (Guideline)
- Cascade counselling and testing. Recommendations of the European Society of Human Genetics 2025 (Guideline)
- Cascade Genetic Risk Education and Testing in Families With Hereditary Cancer Syndromes: A Randomized Clinical Trial 2023 (RCT)
- Privacy and utility of genetic testing in families with hereditary cancer syndromes living in three national healthcare systems: ethical, legal, and social implications 2023
- Recommendations for reporting results of diagnostic genomic testing 2022 (Guideline)
- ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG) 2023 (Position Statement)
Disclaimer
Germline results can affect medical care and biological relatives and should be interpreted with personal history, family history, inheritance, and test limitations. Do not change surveillance, treatment, or reproductive plans based only on an unconfirmed result or VUS. Discuss clinically important findings with the ordering clinician or a qualified genetics professional.
